ArticleInternational journal of legal medicine2026
Evaluation of Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) in serum and cerebrospinal fluid following fatal traumatic brain injury.
Article in International journal of legal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) remains a major contributor to mortality and is frequently the subject of forensic and neuropathological inquiries. In light of ongoing advances in neuroscience and clinical diagnostics, the development of novel bioanalytical methods and data interpretation tools for diagnosing TBI in both living and deceased individuals remains a pressing need. Among the proteins of growing interest are the multifunctional and evolutionarily conserved sirtuin 1 (SIRT1) and sirtuin 3 (SIRT3), due to their adaptive roles in mitochondrial energy metabolism, aging, genomic stability, inflammation, and oncogenesis. This study aimed to determine whether SIRT1 and SIRT3 levels are elevated in post-mortem biofluids, specifically serum and cerebrospinal fluid (CSF) in fatal TBI cases in a population-based autopsy survey. A total of 40 individuals were included, equally divided into two groups, individuals who died from traumatic brain injury (n = 20) and those who died from sudden cardiac or respiratory causes (n = 20), serving as controls. Serum and CSF samples were collected approximately 24 h post-mortem and analyzed using ELISA. The findings demonstrated significantly elevated SIRT1 concentrations in both serum and CSF in the TBI group. Therefore, further analyses demonstrated significantly higher SIRT3 concentrations in serum among study group after TBI. In cases with macroscopically unclear post-mortem abnormalities, a additional assessment of SIRT1 and SIRT3 in body fluids such as serum and CSF might theoretically be utilized to supplementary determination of the cause of death and the magnitude of brain damage for forensic medicine and neuropathological purposes. These findings support the hypothesis that sirtuin expression is altered in the acute phase of TBI and may serve as a useful biomarker in elucidating post-traumatic pathophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.